PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
12.91%
Revenue growth at 50-75% of TSM's 17.42%. Martin Whitman would worry about competitiveness or product relevance.
16.69%
Gross profit growth at 50-75% of TSM's 25.76%. Martin Whitman would question if cost structure or brand is lagging.
91.72%
EBIT growth above 1.5x TSM's 29.71%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
91.72%
Operating income growth above 1.5x TSM's 29.71%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
96.98%
Net income growth above 1.5x TSM's 30.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
92.00%
EPS growth above 1.5x TSM's 30.72%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
92.00%
Diluted EPS growth above 1.5x TSM's 30.72%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.52%
Share count expansion well above TSM's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.10%
Reduced diluted shares while TSM is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
2281.65%
OCF growth above 1.5x TSM's 2.27%. David Dodd would confirm a clear edge in underlying cash generation.
464.38%
FCF growth above 1.5x TSM's 52.73%. David Dodd would verify if the firm’s strategic investments yield superior returns.
80.39%
10Y revenue/share CAGR under 50% of TSM's 266.60%. Michael Burry would suspect a lasting competitive disadvantage.
-1.28%
Negative 5Y CAGR while TSM stands at 82.23%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
18.76%
3Y revenue/share CAGR under 50% of TSM's 48.39%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
22097.04%
10Y OCF/share CAGR above 1.5x TSM's 206.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-46.36%
Negative 5Y OCF/share CAGR while TSM is at 81.89%. Joel Greenblatt would question the firm’s operational model or cost structure.
31.30%
3Y OCF/share CAGR at 50-75% of TSM's 53.64%. Martin Whitman would suspect weaker recent execution or product competitiveness.
1572.42%
Net income/share CAGR above 1.5x TSM's 580.58% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
-39.06%
Negative 5Y net income/share CAGR while TSM is 80.18%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
199.84%
3Y net income/share CAGR above 1.5x TSM's 28.50%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
272.06%
10Y equity/share CAGR above 1.5x TSM's 163.73%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
74.22%
5Y equity/share CAGR is in line with TSM's 68.38%. Walter Schloss would see parallel mid-term profitability and retention policies.
75.00%
3Y equity/share CAGR 1.25-1.5x TSM's 51.26%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.31%
AR growth is negative/stable vs. TSM's 25.26%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
12.98%
Inventory growth well above TSM's 2.07%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.22%
Asset growth well under 50% of TSM's 10.20%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.34%
Positive BV/share change while TSM is negative. John Neff sees a clear edge over a competitor losing equity.
-2.85%
We’re deleveraging while TSM stands at 23.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.95%
Our R&D shrinks while TSM invests at 12.12%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
12.44%
SG&A growth well above TSM's 19.65%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.